Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

Open Access 01-05-2012 | Inflammatory Disorders

Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis

Authors: R. J. Erckens, R. L. M. Mostard, P. A. H. M. Wijnen, J. S. Schouten, M. Drent

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 5/2012

Abstract

Introduction

Adalimumab, a humanized monoclonal antibody targeted against TNF-α, has proved to be successful in the treatment of uveitis. Another anti-TNF-α agent, i.e., infliximab, has been reported of benefit in the treatment of refractory sarcoidosis. The aim of this prospective case series was to evaluate the effect of adalimumab on intraocular inflammatory signs and other relevant clinical manifestations (lung function, serological inflammatory parameters, and fatigue) of sarcoidosis.

Methods

Sarcoidosis patients with refractory posterior uveitis (n = 26, 17 females, 41 eyes in total) were systematically followed for 12 months after initiation of adalimumab 40 mg sc once a week. Inclusion criteria were non-responsiveness to prednisone and methotrexate (MTX) or intolerance to these drugs. Adjunctive therapy with prednisone and MTX was tapered during treatment with adalimumab. Localization and improvement, stabilization or deterioration of intraocular inflammatory signs was scored. Pulmonary function- and laboratory testing were performed and Fatigue Assessment Scale was completed. Results at baseline, 6 months, and 12 months were compared.

Results

Choroidal involvement resolved in 10/15 patients, five had partial improvement; vasculitis resolved in 1/1 patient; papillitis resolved in 7/8 patients, one had partial response; macular edema resolved in 5/8 patients, three had partial response; vitreous cleared completely in 5/5 patients. Overall outcome regarding intraocular inflammatory signs showed improvement in 22 patients (85%) and stabilization in four patients (15%). At 12 months, no recurrences were reported in those successfully treated. Laboratory parameters of inflammatory activity (C-reactive protein; serum angiotensin-converting enzyme and soluble interleukin-2 Receptor) improved (p < 0.01). Moreover, fatigue improved in 14/21 (67%) of the patients suffering from fatigue and the diffusion capacity for carbon monoxide (DLCO) improved in 7/8 (88%) of patients with a decreased DLCO (p < 0.01). The dosage of both prednisone and MTX could be tapered down significantly (p < 0.01 and p < 0.05, respectively).

Conclusions

Adalimumab appeared successful in sarcoidosis patients with refractory chronic non-infectious uveitis showing improvement in intraocular inflammatory signs as well as in other relevant clinical indicators of disease activity. Future randomized studies are needed to determine the optimal dosage, dose interval and duration of therapy in refractory multisystemic sarcoidosis.

Rothova A (2000) Ocular involvement in sarcoidosis. Br J Ophthalmol 84:110–116PubMedCrossRef

Kosmorsky GS, Meisler DM, Rice TW, Meziane MA, Lowder CY (1998) Chest computed tomography and mediastinoscopy in the diagnosis of sarcoidosis-associated uveitis. Am J Ophthalmol 126:132–134PubMedCrossRef

Iannuzzi MC, Rybicki BA, Teirstein AS (2007) Sarcoidosis. N Engl J Med 357:2153–2165PubMedCrossRef

Herbort CP, Rao NA, Mochizuki M (2009) International criteria for the diagnosis of ocular sarcoidosis: results of the first International Workshop On Ocular Sarcoidosis (IWOS). Ocul Immunol Inflamm 17:160–169PubMedCrossRef

Martin TM, Doyle TM, Smith JR, Dinulescu D, Rust K, Rosenbaum JT (2003) Uveitis in patients with sarcoidosis is not associated with mutations in NOD2 (CARD15). Am J Ophthalmol 136:933–935PubMedCrossRef

Dana MR, Merayo-Lloves J, Schaumberg DA, Foster CS (1996) Prognosticators for visual outcome in sarcoid uveitis. Ophthalmology 103:1846–1853PubMed

Ardoin SP, Kredich D, Rabinovich E, Schanberg LE, Jaffe GJ (2007) Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up. Am J Ophthalmol 144:844–849PubMedCrossRef

Dev S, McCallum RM, Jaffe GJ (1999) Methotrexate treatment for sarcoid-associated panuveitis. Ophthalmology 106:111–118PubMedCrossRef

Baughman RP, Lower EE, Drent M (2008) Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them. Sarcoidosis Vasc Diffuse Lung Dis 25:76–89PubMed

10.

Baughman RP, Costabel U, du Bois RM (2008) Treatment of sarcoidosis. Clin Chest Med 29:533–548, ix-xPubMedCrossRef

11.

Elfferich MD, Nelemans PJ, Ponds RW, Vries JD, Wijnen PA, Drent M (2010) Everyday Cognitive Failure in Sarcoidosis: the Prevalence and the Effect of Anti-TNF-α- treatment. Respiration

12.

Baughman RP, Drent M, Kavuru M, Judson MA, Costabel U, du Bois R, Albera C, Brutsche M, Davis G, Donohue JF, Muller-Quernheim J, Schlenker-Herceg R, Flavin S, Lo KH, Oemar B, Barnathan ES (2006) Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 174:795–802PubMedCrossRef

13.

Baughman RP, Lower EE (2001) Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 18:70–74PubMed

14.

Galor A, Perez VL, Hammel JP, Lowder CY (2006) Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 113:2317–2323PubMedCrossRef

15.

Hale S, Lightman S (2006) Anti-TNF therapies in the management of acute and chronic uveitis. Cytokine 33:231–237PubMedCrossRef

16.

Sobrin L, Kim EC, Christen W, Papadaki T, Letko E, Foster CS (2007) Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol 125:895–900PubMedCrossRef

17.

Petropoulos IK, Vaudaux JD, Guex-Crosier Y (2008) Anti-TNF-alpha therapy in patients with chronic non-infectious uveitis: the experience of Jules Gonin Eye Hospital. Klin Monbl Augenheilkd 225:457–461PubMedCrossRef

18.

Lindstedt EW, Baarsma GS, Kuijpers RW, van Hagen PM (2005) Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol 89:533–536PubMedCrossRef

19.

Takase K, Ohno S, Ideguchi H, Uchio E, Takeno M, Ishigatsubo Y (2011) Successful switching to adalimumab in an infliximab-allergic patient with severe Behçet disease-related uveitis. Rheumatol Int 31:243–245PubMedCrossRef

20.

Seiderer J, Brand S, Dambacher J, Pfennig S, Jurgens M, Goke B, Ochsenkuhn T (2007) Adalimumab in patients with Crohn's disease–safety and efficacy in an open-label single centre study. Aliment Pharmacol Ther 25:787–796PubMedCrossRef

21.

Simonini G, Taddio A, Cattalini M, Caputo R, De Libero C, Naviglio S, Bresci C, Lorusso M, Lepore L, Cimaz R (2010) Prevention of flare recurrences in childhood refractory chronic uveitis: an open-label comparative study of Adalimumab versus Infliximab. Arthritis Care Res (Hoboken)

22.

Kamphuis L WL-T, Dik W, et al. (2011) Efficacy of adalimumab in chronically active and symptomatic sarcoidosis patients. American Journal of Respiratory and Critical Care Medicine (in press)

23.

Callejas-Rubio JL, Ortego-Centeno N, Lopez-Perez L, Benticuaga MN (2006) Treatment of therapy-resistant sarcoidosis with adalimumab. Clin Rheumatol 25:596–597PubMedCrossRef

24.

Field S, Regan AO, Sheahan K, Collins P (2010) Recalcitrant cutaneous sarcoidosis responding to adalimumab but not to etanercept. Clin Exp Dermatol 35:795–796PubMedCrossRef

25.

Philips MA, Lynch J, Azmi FH (2005) Ulcerative cutaneous sarcoidosis responding to adalimumab. J Am Acad Dermatol 53:917PubMedCrossRef

26.

Heffernan MP, Smith DI (2006) Adalimumab for treatment of cutaneous sarcoidosis. Arch Dermatol 142:17–19PubMedCrossRef

27.

Hunninghake GW, Costabel U, Ando M, Baughman R, Cordier JF, du Bois R, Eklund A, Kitaichi M, Lynch J, Rizzato G, Rose C, Selroos O, Semenzato G, Sharma OP (1999) ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 16:149–173PubMed

28.

Bartalesi F, Vicidomini S, Goletti D, Fiorelli C, Fiori G, Melchiorre D, Tortoli E, Mantella A, Benucci M, Girardi E, Cerinic MM, Bartoloni A (2009) QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases. Eur Respir J 33:586–593PubMedCrossRef

29.

Jabs DA, Nussenblatt RB, Rosenbaum JT (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140:509–516PubMedCrossRef

30.

Mostard RL, Voo S, van Kroonenburgh MJ, Verschakelen JA, Wijnen PA, Nelemans PJ, Erckens RJ, Drent M (2011) Inflammatory activity assessment by F18 FDG-PET/CT in persistent symptomatic sarcoidosis. Respir Med 2011 Sep 5 [Epub ahead of print]

31.

de Kleijn WP, Elfferich MD, De Vries J, Jonker GJ, Lower EE, Baughman RP, King TE Jr, Drent M (2009) Fatigue in sarcoidosis: American versus Dutch patients. Sarcoidosis Vasc Diffuse Lung Dis 26:92–97PubMed

32.

Akova YA, Foster CS (1994) Cataract surgery in patients with sarcoidosis-associated uveitis. Ophthalmology 101:473–479PubMed

33.

Sandborn WJ, Hanauer S, Loftus EV Jr, Tremaine WJ, Kane S, Cohen R, Hanson K, Johnson T, Schmitt D, Jeche R (2004) An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 99:1984–1989PubMedCrossRef

34.

Baughman RP (2007) Tumor necrosis factor inhibition in treating sarcoidosis: the American experience. Revista Portuguesa de Pneumonologia 13:S47–S50

35.

Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT (2006) The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54:26–37PubMedCrossRef

36.

Breban M, Ravaud P, Claudepierre P, Baron G, Henry YD, Hudry C, Euller-Ziegler L, Pham T, Solau-Gervais E, Chary-Valckenaere I, Marcelli C, Perdriger A, Le Loet X, Wendling D, Fautrel B, Fournie B, Combe B, Gaudin P, Jousse S, Mariette X, Baleydier A, Trape G, Dougados M (2008) Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum 58:88–97PubMedCrossRef

37.

van Riel PL, Taggart AJ, Sany J, Gaubitz M, Nab HW, Pedersen R, Freundlich B, MacPeek D (2006) Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. Ann Rheum Dis 65:1478–1483PubMedCrossRef

38.

Wolbink GJ, Voskuyl AE, Lems WF, de Groot E, Nurmohamed MT, Tak PP, Dijkmans BA, Aarden L (2005) Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 64:704–707PubMedCrossRef

39.

Gratacos J, Casado E, Real J, Torre-Alonso JC (2007) Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate. Ann Rheum Dis 66:493–497PubMedCrossRef

40.

Stone MA, Payne U, Pacheco-Tena C, Inman RD (2004) Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis. Ann Rheum Dis 63:84–87PubMedCrossRef

41.

Louis E, Vermeire S, Rutgeerts P, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, D'Haens G, Malaise M, Belaiche J (2002) A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with −308 TNF gene polymorphism. Scand J Gastroenterol 37:818–824PubMed

42.

Sweiss NJ, Barnathan ES, Lo K, Judson MA, Baughman R (2010) C-reactive protein predicts response to infliximab in patients with chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 27:49–56PubMed

43.

Keijsers RG, Verzijlbergen JF, van Diepen DM, van den Bosch JM, Grutters JC (2008) 18 F-FDG PET in sarcoidosis: an observational study in 12 patients treated with infliximab. Sarcoidosis Vasc Diffuse Lung Dis 25:143–149PubMed

Title: Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis
Authors: R. J. Erckens
R. L. M. Mostard
P. A. H. M. Wijnen
J. S. Schouten
M. Drent
Publication date: 01-05-2012
Publisher: Springer-Verlag
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 5/2012
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-011-1844-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis

Abstract

Introduction

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2012

Retrospective review of 50 eyes with long-term silicone oil tamponade for more than 12 months

GM-CSF protects rat photoreceptors from death by activating the SRC-dependent signalling and elevating anti-apoptotic factors and neurotrophins

Benign reactive lymphoid hyperplasia affecting both the conjunctiva and the cornea

Pigment dispersion secondary to anterior chamber angle recession

Association of dilated retinal arteriolar caliber with early age-related macular degeneration: the Handan Eye Study

Methylglyoxal induces hyperpermeability of the blood–retinal barrier via the loss of tight junction proteins and the activation of matrix metalloproteinases